PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX). This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen (NASDAQ: AMGN).

加利福尼亚州帕萨迪纳市（商业新闻短讯）--箭头制药公司（NASDAQ:ARWR）今天宣布，已收到Royalty Pharma plc（NASDAQ:RPRX）的5000万美元里程碑付款。这一里程碑事件是在Amgen（纳斯达克股票代码：AMGN）进行的olpasiran第三阶段OCEAN（a）-结果试验注册完成后触发的。

Pursuant to its 2016 agreement with Amgen and 2022 agreement with Royalty Pharma, Arrowhead is further eligible to receive up to an additional $375 million from Amgen and $110 million from Royalty Pharma in aggregate development, regulatory, and sales milestone payments associated with olpasiran..

根据其与安进公司的2016年协议和与皇家制药公司的2022年协议，Arrowhead还有资格从安进公司获得高达3.75亿美元的额外款项，并从皇家制药公司获得1.1亿美元的与olpasiran相关的开发、监管和销售里程碑付款。。

“The rapid enrollment of the OCEAN(a) - Outcomes Trial demonstrates the strong interest in olpasiran, developed using Arrowhead’s proprietary TRiMTM technology and licensed to Amgen in 2016. Partnering is an important part of our strategy and we are pleased with all the care and work undertaken to bring this potentially important new therapy closer to patients,” said Christopher Anzalone, Ph.D., Arrowhead’s president and CEO.

“OCEAN（a）-Outcomes试验的快速注册表明了人们对olpasiran的浓厚兴趣，olpasiran是使用Arrowhead专有的TRiMTM技术开发的，并于2016年获得安进公司的许可。合作是我们战略的重要组成部分，我们很高兴为使这种潜在重要的新疗法更接近患者而进行的所有护理和工作，”箭头总裁兼首席执行官克里斯托弗·安佐隆博士说。

“Our pipeline of wholly owned or partnered TRiMTM-enabled candidates now includes three programs in Phase 3 - olpasiran, fazirsiran, and plozasiran. Importantly, our lead wholly owned candidate plozasiran, a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of Apolipoprotein C-III (APOC3), is on schedule to complete its first pivotal Phase 3 study this quarter, with a topline readout soon after.”.

“我们的全资或合作TRiMTM候选人渠道现在包括第三阶段的三个项目-olpasiran，fazirsiran和plozasiran。重要的是，我们的首席全资候选人plozasiran是一种一流的研究性RNA干扰（RNAi）治疗剂，旨在减少载脂蛋白C-III（APOC3）的产生，预计将于本季度完成其第一个关键的第三阶段研究，并在不久后公布结果。”。

Olpasiran is a small interfering RNA (siRNA) originally developed by Arrowhead using its proprietary Targeted RNAi Molecule (TRiMTM) platform. It is designed to lower levels of lipoprotein(a) (Lp(a)), a genetically determined risk factor for cardiovascular disease. The primary objective of the Phase 3 OCEAN(a) - Outcomes Trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death, myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease and elevated lipoprotein(a)..

Olpasiran是一种小干扰RNA（siRNA），最初由Arrowhead使用其专有的靶向RNAi分子（TRiMTM）平台开发。它旨在降低脂蛋白（a）（Lp（a））的水平，Lp（a））是遗传决定的心血管疾病危险因素。第三阶段OCEAN（a）-结果试验的主要目的是比较olpasiran治疗与安慰剂治疗对动脉粥样硬化性心血管疾病和脂蛋白（a）升高参与者冠心病死亡，心肌梗死或紧急冠状动脉血运重建风险的影响。。

About Lp(a)

关于Lp（a）

Lp(a) is primarily genetically determined1-3 and a presumed independent risk factor for cardiovascular disease (CVD). Although an agreed upon threshold for elevated Lp(a) is not firmly established, approximately 20% of adults have Lp(a) >125 nmol/L (or approximately 50 mg/dL).1 Evidence has emerged from pathophysiological, epidemiologic, and genetic studies on the potential role of elevated Lp(a) in contributing to myocardial infarction, stroke, and peripheral arterial disease.3.

Lp（a）主要由基因决定1-3，是心血管疾病（CVD）的独立危险因素。虽然Lp（a）升高的商定阈值尚未确定，但大约20%的成年人Lp（a）>125 nmol/L（或约50 mg/dL）[1]。病理生理学，流行病学和遗传学研究表明Lp（a）升高在心肌梗死，中风和外周动脉疾病中的潜在作用。

About Arrowhead Pharmaceuticals

关于箭头制药

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.

箭头制药公司通过沉默导致顽固性疾病的基因来开发治疗顽固性疾病的药物。使用广泛的RNA化学组合和有效的递送方式，箭头疗法触发RNA干扰机制，以诱导靶基因的快速，深入和持久的敲低。

RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing..

RNA干扰（RNAi）是活细胞中存在的一种机制，可抑制特定基因的表达，从而影响特定蛋白质的产生。Arrowhead基于RNAi的疗法利用了这种基因沉默的自然途径。。

For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma or on LinkedIn. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

欲了解更多信息，请访问www.arrowheadharma.com，或通过X（以前的推特）关注我们@arrowheadharma或LinkedIn。要添加到公司的电子邮件列表并直接接收新闻，请访问http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

私人证券诉讼改革法案下的安全港声明：

This news release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》中“安全港”条款所指的前瞻性声明。除历史信息外，本版本中包含的任何声明都可能被视为前瞻性声明。在不限制上述一般性的情况下，诸如“可能”、“将”、“预期”、“相信”、“预期”、“希望”、“打算”、“计划”、“项目”、“可能”、“估计”、“继续”、“目标”、“预测”或“继续”等词语或其其他变体或类似术语的否定词旨在识别此类前瞻性陈述。

In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements.

此外，任何涉及我们未来财务业绩预测、业务趋势、对我们产品线或候选产品的期望的陈述，包括预期的监管提交和临床计划结果、我们与其他公司合作的前景或利益，或未来事件或情况的其他特征，都是前瞻性陈述。

These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties.

这些前瞻性陈述包括但不限于关于我们的临床前研究和临床试验以及我们的研究和开发计划的开始，时间，进展和结果的陈述；我们对合作伙伴关系、许可和/或合作安排以及我们已经达成或将来可能达成的其他战略安排和交易的潜在利益的期望；我们对里程碑、特许权使用费或现有协议下可能应付给第三方或来自第三方的其他付款的信念和期望；以及我们对未来收入、研发费用、资本要求和向第三方付款的估计。

These statements are based u.

这些声明基于美国。

Source: Arrowhead Pharmaceuticals, Inc.

来源：Arrowhead Pharmaceuticals，Inc。

________________

________________

Wilson DP, et al. Clin Lipidol. 2019;13(3):374-92.

Wilson DP等人，Clin Lipidol。2019年；13（3）：374-92。

Reyes-Soffer G, et al. Arterioscler Thromb Vasc Biol. 2022;42(1):e48-e60.

Reyes Soffer G等。动脉血栓血管生物学。2022;42（1）：e48-e60。

Tsimikas S, et al. J Am Coll Cardiol. 2018;71(2): 177–192.

Tsimikas S等，《美国心血管杂志》。2018;71(2): 177–192.